Compare AMKR & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMKR | MEDP |
|---|---|---|
| Founded | 1968 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3B | 12.9B |
| IPO Year | 1997 | 2016 |
| Metric | AMKR | MEDP |
|---|---|---|
| Price | $42.98 | $479.99 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 13 |
| Target Price | $52.88 | ★ $498.25 |
| AVG Volume (30 Days) | ★ 4.7M | 433.2K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.80% | N/A |
| EPS Growth | 4.90 | ★ 20.98 |
| EPS | 1.50 | ★ 15.28 |
| Revenue | ★ $4,052,650,000.00 | N/A |
| Revenue This Year | $13.21 | $13.11 |
| Revenue Next Year | $9.80 | $7.51 |
| P/E Ratio | ★ $27.79 | $30.87 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.03 | $250.05 |
| 52 Week High | $57.09 | $628.92 |
| Indicator | AMKR | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 40.93 | 47.77 |
| Support Level | $39.07 | $457.41 |
| Resistance Level | $47.28 | $501.30 |
| Average True Range (ATR) | 2.29 | 17.21 |
| MACD | -0.76 | 8.48 |
| Stochastic Oscillator | 23.35 | 94.27 |
Amkor Technology Inc is a OSAT (outsourced semiconductor assembly and test) service provider. It has pioneered the outsourcing of integrated circuit (IC) packaging and test services and is a strategic manufacturing partner for the semiconductor companies, foundries, and electronics original equipment manufacturers (OEMs). The firm's products are organized into two categories namely advanced products that include flip chip, fine pitch bumping, wafer-level processing, advanced SiPs, power modules, and others, and Mainstream products that includes wirebond packaging and testing. The company derives maximum revenue from the advanced products category. The company derives majority of its revenue from Foreign states.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.